Highlights newsletter 3
This newsletter presents you the following key sessions:
1. Video-interview with Dr. Sébastien Maury on the Graall-R 2005 study in which adding rituximab improved the
outcome of adult patients with CD20-positive, Ph-negative B-cell precursor acute lymphoblastic leukemia
2. Nivolumab is associated with a high response rate in patients with classical Hodgkin lymphoma
3. Adding carfilzomib to lenalidomide and dexamethasone adds 9 months of progression-free survival in relapsed
multiple myeloma patients with high-risk cytogenetic abnormalities
4. Obinutuzumab plus bendamustine: a new treatment option for patients with untreated CLL
5. Sustained clinical benefit and confirmed longer survival with ruxolitinib in patients with myelofibrosis: 5-year
follow-up of COMFORT-II